Viking's key drug demonstrated excellent body weight reduction data in a phase 2 trial, but its safety and tolerability data ...

Viking Therapeutics, Inc.'s obesity drug VK2735 results reveal no clear edge over leading competitors. Click for why this ...

We recently published 10 Stocks Hammered Harder Than Wall Street. Viking Therapeutics, Inc. (NASDAQ:VKTX) is one of Tuesday’s ...

The oral formulation led to up to 12.2% weight loss over three months, a weaker outcome versus late-stage treatments from Eli ...

Viking Therapeutics (NASDAQ: VKTX) stock collapsed on Tuesday, down 41.4% through 10:25 a.m. ET after reporting what ...

The Phase II VENTURE-Oral Dosing study of VK2735 met primary and secondary endpoints, with once-daily treatment leading to progressive weight reductions, high responder rates, and encouraging safety ...

Viking Therapeutics reported a large number of patients dropped out of a study of its experimental weight-loss pill.

Viking Therapeutics (VKTX) stock drops even as a mid-stage trial for its oral weight loss drug VK2735 succeeds. Novo (NVO) ...

The company’s market value was nearly cut in half following trial results showing higher rates of treatment discontinuations ...

Viking Therapeutics reported positive Phase 2 results for VK2735, showing significant weight loss and safety in obesity ...

Current health news highlights include Viking's weight-loss pill failing to meet financial expectations, European corporate ...

The company is the latest facing historic losses as pharmaceutical firms compete to develop a weight-loss pill.